Counting for Cancer: Digital Detection of Rare Mutant DNA MoleculesSpeaker: Kenneth W. Kinzler, Ph.D., Professor, Oncology; Director, Ludwig Center at Johns Hopkins University, The Johns Hopkins Kimmel Cancer Center
" Under licensing agreements between the companies listed below and the Johns Hopkins University, Dr. Kinzler is entitled to a share of royalty and milestone payments received by the University on sales of products related to previous and ongoing research in the lab. Dr. Kinzler also has ownership interest in Inostics and PGDx. The terms of these arrangements are being managed by the Johns Hopkins University in accordance with its conflict of interest policies.
PGDx, Inostics, Exact Sciences Corporation, Genzyme Corporation, Agencourt, GMP Companies, Morphotek, Calbiochem Novabiochem, Wyeth, Amgen, Merck, OncoMethylome Sciences, GanyMed, Bayer Corporation, 454 Life Sciences, Corixa Corp, Q-Biogene, Smithkline-Beecham, Stratagene, Yamanouchi Pharmaceuticals, Zymogenetics, Qbiogene, Quantum Biotech, Zymogenetics "
* - required fields
250 First Avenue Suite 300Needham, MA 02494P: 781.972.5400F: 781.972.5425E: email@example.com
biological therapeutic productsbiomarkers & diagnosticsbiopharma strategybioprocess & manufacturingchemistryclinical trials & translational medicinedrug & device safety
drug discovery & developmentdrug targetsgenomicshealthcareit & informaticstechnology & tools for life sciencetherapeutic indications
conferencesreportsbarnett educational servicesconsultingpublications & eNewslettersKnowledge Foundation professional services
executive teamtestimonialschi timelinemailing listcareers